



PRESS RELEASE

25 November 2024 20:40:00 CET

AcouSort secures working capital through H1, 2025

Through a consortium consisting of the company's management, board of directors, founders and major shareholders, AcouSort has received loan guarantees of approximately SEK 4.5 million. Together with current cash position and known future revenues, the loan guarantees secure the execution of AcouSort's planned activities into Q3 of 2025. AcouSort will now work to establish the best possible financing for the company's next development phase.

The loan facility gives AcouSort the right to request disbursement of all or part of the loan from the lenders if the company deems that there is a need for financing. Unless the parties have agreed otherwise, the disbursed part of the loan must be repaid together with accrued interest no later than 31 December 2025. However, AcouSort has the right to freely repay all or part of the loan early. The setup fee for the loan agreement is 1% and the interest to be paid if the loans are drawn is in line with current market conditions.

“Our current cash position including known future revenues and royalties from Werfen will take us well into Q2. The reason for securing loan guarantees at this stage is to provide AcouSort with ample time to establish the best possible financing partnerships going forward. For me it is gratifying to see that the company's management and board alongside major shareholders share my conviction of the company's great potential within advanced healthcare,” says AcouSort's CEO Torsten Freltoft.

This information is information that AcouSort is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-11-25 20:40 CET.

FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT:

Torsten Freltoft, CEO

Telephone: +45 2045 0854

E-mail: torsten.freltoft@acousort.com

ABOUT ACOUSORT

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of-Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Carnegie Investment Bank AB (publ).



PRESS RELEASE

25 November 2024 20:40:00 CET